An Intervention Study for Adults with Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
Proof-of-Activity Study with Orticumab in Subjects with Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
SEX AT BIRTH: All
CONDITION: Plaque psoriasis
LOCATION: University Hospitals Cleveland Medical Center
The purpose of this research study is to test an experimental drug called Orticumab, a monocolonal antibody, to assess the safety and tolerability in subjects with moderate-to-severe psoriasis and cardiometabolic risk factors (obesity, high low-density lipoprotein (also called “LDL” or “bad” cholesterol), high blood fat (triglycerides), low high-density lipoprotein (also called “HDL” or “good” cholesterol), high blood pressure, diabetes, smoking tobacco).
Who Can Participate
Participants 30 years and older diagnosed with plaque psoriasis, have a BMI equal to or greater than 30 and whose LDL is greater than 100 mg/dL at the time of screening may be eligible for this study.